Abstract
Two randomised controlled trials have shown that maintenance of blood glucose levels below 110 mg/dl with intensive insulin therapy reduces mortality and morbidity of surgical and medical critically ill patients. An absolute reduction in the risk of death of 3-4 % is expected in intention-to-treat analysis, but the survival benefit increases when treatment is continued for at least a few days. Future studies set up to confirm the survival benefit and assign it as statistically significant in an intention-to-treat medical patient population should be adequately powered with inclusion of at least 5000 patients. For the observed benefits of intensive insulin therapy strict maintenance of normoglycaemia is primordial, whereas glycaemia- independent actions of insulin have minor, organ-specific impact. Pathophysiological mechanisms underlying the clinical effects are currently being unravelled further and might help to find new strategies for further improving outcome. Implementation of a strict glycemic control protocol in the intensive care unit is feasible and cost-effective, but asks for careful consideration of some practical aspects, such as prevention of hypoglycaemia, training of nurses and selection of accurate blood glucose measurement tools. Continuous blood glucose monitoring devices and closed-loop systems are under development and might be of great benefit to overcome these issues.
Keywords: Insulin Therapy, Blood Glucose, normoglycaemia, Pathophysiological mechanisms, hypoglycaemia, Continuous blood glucose monitoring devices, closed-loop systems
Current Diabetes Reviews
Title: The Importance of Strict Blood Glucose Control with Insulin Therapy in the Intensive Care Unit
Volume: 4 Issue: 3
Author(s): Ingeborg van den Heuvel, Ilse Vanhorebeek and Great Van den Berghe
Affiliation:
Keywords: Insulin Therapy, Blood Glucose, normoglycaemia, Pathophysiological mechanisms, hypoglycaemia, Continuous blood glucose monitoring devices, closed-loop systems
Abstract: Two randomised controlled trials have shown that maintenance of blood glucose levels below 110 mg/dl with intensive insulin therapy reduces mortality and morbidity of surgical and medical critically ill patients. An absolute reduction in the risk of death of 3-4 % is expected in intention-to-treat analysis, but the survival benefit increases when treatment is continued for at least a few days. Future studies set up to confirm the survival benefit and assign it as statistically significant in an intention-to-treat medical patient population should be adequately powered with inclusion of at least 5000 patients. For the observed benefits of intensive insulin therapy strict maintenance of normoglycaemia is primordial, whereas glycaemia- independent actions of insulin have minor, organ-specific impact. Pathophysiological mechanisms underlying the clinical effects are currently being unravelled further and might help to find new strategies for further improving outcome. Implementation of a strict glycemic control protocol in the intensive care unit is feasible and cost-effective, but asks for careful consideration of some practical aspects, such as prevention of hypoglycaemia, training of nurses and selection of accurate blood glucose measurement tools. Continuous blood glucose monitoring devices and closed-loop systems are under development and might be of great benefit to overcome these issues.
Export Options
About this article
Cite this article as:
Heuvel van den Ingeborg, Vanhorebeek Ilse and Berghe Van den Great, The Importance of Strict Blood Glucose Control with Insulin Therapy in the Intensive Care Unit, Current Diabetes Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339908785294343
DOI https://dx.doi.org/10.2174/157339908785294343 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Apoptosis Modulated by Oxidative Stress and Inflammation During Obstructive Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, its Potential Benefit in Angina and Other Cardiovascular Disorders
Recent Patents on Cardiovascular Drug Discovery Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Exercise Preconditioning Reduces Brain Damage and Inhibits TNF-α Receptor Expression after Hypoxia/Reoxygenation: An In Vivo and In Vitro Study
Current Neurovascular Research Exogenous Factors from Venomous and Hematophagous Animals in Drugs and Diagnostic Developments for Cardiovascular and Neurovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies
Cardiovascular & Hematological Disorders-Drug Targets Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Effect of Rehabilitative Exercise Training on Peripheral Muscle Remodelling in Patients with COPD: Targeting Beyond the Lungs
Current Drug Targets Transcatheter Aortic Valve Technology: Current State
Recent Patents on Biomedical Engineering (Discontinued) A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets